Article

Mitigating Temozolomide Resistance in Glioblastoma via DNA Damage-Repair Inhibition

2019-10-05

Abstract excerpt

Glioblastomas are among the most lethal cancers, with a five year survival rate below 25%. Temozolomide is typically used in glioblastoma treatment; however, the enzymes APNG and MGMT efficiently mediate the repair of DNA damage caused by temozolomide, reducing treatment efficacy. Consequently, APNG and MGMT inhibition has been proposed as a way of overcoming chemotherapy resistance. Here, we develop a mechanistic...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 362867fe-adf9-5f97-b91b-e3dfff853ba9
DOI: 10.1101/794115

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Mitigating Temozolomide Resistance in Glioblastoma via DNA Damage-Repair InhibitionDOI 10.1101/794115Read

Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibitionSemantic proximity Read

A multifaceted review of temozolomide resistance mechanisms in glioblastoma beyond O-6-methylguanine-DNA methyltransferaseSemantic proximity Read

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive reviewSemantic proximity Read

Mechanisms of Resistance to Current Glioblastoma TherapiesSemantic proximity Read

Potential Strategies Overcoming the Temozolomide Resistance for GlioblastomaSemantic proximity Read

Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patientsSemantic proximity Read

Research progress of drug resistance mechanism of temozolomide in the treatment of glioblastomaSemantic proximity Read

DNA damage repair in glioblastoma: current perspectives on its role in tumour progression, treatment resistance and PIKKing potential therapeutic targetsSemantic proximity Read

Characterization of Temozolomide Resistance Using a Novel Acquired Resistance Model in Glioblastoma Cell LinesSemantic proximity Read

Toward an effective strategy in glioblastoma treatment. Part I: resistance mechanisms and strategies to overcome resistance of glioblastoma to temozolomide.Semantic proximity Read

Novel approaches for glioblastoma treatment: Focus on tumor heterogeneity, treatment resistance, and computational tools.Semantic proximity Read

Identification of inter- and intra-tumoral molecular phenotypes steering temozolomide resistance in patient-derived glioblastoma cellsSemantic proximity Read